This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): Aslera, Anastar, dehydroepiandrostenedione, DHEA, GL701, Prasterone
Description: The active ingredient of Prestara is Prasterone. It is the synthetic analog ofdehydroepiandrosterone (DHEA), the most abundant adrenal hormone in humans.
Watson and Genelabs
In November 2000, Watson Pharmaceuticals and Genelabs Technologies entered into a collaboration and license agreement which includes marketing rights for Prestara. Watson paid Genelabs fees and milestone payments of up to $55 million, including a $10 million non-refundable initial license fee and payable milestones payments. In addition, Genelabs will receive significant royalties on net sales of and retains future co-marketing rights.
In January 2013, Watson changed its name to Actavis.
Genelabs and Tanabe Seiyaku
In January 2004, Genelabs and Tanabe Seiyaku signed a collaboration and license agreement. The agreement provided that Tanabe was responsible for conducting all development work and obtaining regulatory approval for Prestara in Japan. Under the terms of the agreement, Genelabs received an initial $2 million non-refundable license fee. In addition, $10 million of milestone payments were to be made on the achievement of...See full deal structure in Biomedtracker
Partners: Allergan plc
Pink Sheet Genelabs Prestara “approvable”
Pink Sheet Genelabs Prestara update
Pink Sheet Prestara fails confirmatory trial
Additional information available to subscribers only: